Compare NHI & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NHI | LQDA |
|---|---|---|
| Founded | 1991 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.1B |
| IPO Year | 1991 | 2018 |
| Metric | NHI | LQDA |
|---|---|---|
| Price | $82.76 | $43.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $85.20 | $38.60 |
| AVG Volume (30 Days) | 207.6K | ★ 2.3M |
| Earning Date | 02-26-2026 | 03-18-2026 |
| Dividend Yield | ★ 4.54% | N/A |
| EPS Growth | ★ 8.88 | N/A |
| EPS | ★ 3.17 | N/A |
| Revenue | ★ $357,572,000.00 | $69,216,000.00 |
| Revenue This Year | $7.18 | $993.31 |
| Revenue Next Year | $14.87 | $219.14 |
| P/E Ratio | $25.60 | ★ N/A |
| Revenue Growth | 8.40 | ★ 343.41 |
| 52 Week Low | $65.23 | $11.26 |
| 52 Week High | $82.39 | $46.67 |
| Indicator | NHI | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 62.22 | 61.82 |
| Support Level | $78.73 | $41.09 |
| Resistance Level | $82.39 | $46.67 |
| Average True Range (ATR) | 1.96 | 2.63 |
| MACD | 0.24 | 0.31 |
| Stochastic Oscillator | 96.16 | 68.29 |
National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments, i.e., Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment, which generates maximum revenue, consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived in the form of rental income, mortgage and other notes receivable interest income, and resident fees and services.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.